Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617

Eligibility Criteria

• 1. ≥18 years of age
• 2. Histologic documentation of prostate adenocarcinoma
• 3. Metastatic disease, documented by imaging. Imaging performed within 56 days prior to Screening is acceptable
• 1. Current or prior evidence of any small cell or neuroendocrine histology on the most recent prostate biopsy
• 2. Any liver metastases confirmed by biopsy or evidence of lesions \>1 cm consistent with liver metastases on imaging
• 3. Intervention with any chemotherapy, investigational agent, or other anticancer drug, including enzalutamide, apalutamide, or darolutamide, 14 days prior to Screening or 5 half-live20.
• 4. Any other serious underlying medical, psychiatric, psychological, familial, or geographical condition, which in the judgment of the Investigator may interfere with study participation and compliance or place the participant at high risk from treatment-related complicationss from the last dose (whichever is shorter)